News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
90
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2221
|
|
Created
|
01/15/15
|
Type
|
Free
|
| Moderators | |||
Akers Biosciences mission is dedicated to solving global health challenges. Akers was founded in 1989 and has over
30 years of success in the health diagnostic industry having developed proprietary, in vitro diagnostic technologies.
In March of 2020, in an attempt to further their mission, Akers announced a strategic partnership with Premas Biotech.
The partnerships primary objective is to focus on novel vaccine candidates.
The emergence of this pandemic offers an opportunity for the company to be a solution in the healthcare space,
one that sets the stage for our next chapter of growth.
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.
The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.
Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.
We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
PIFA® technology is currently used in:
Licensing Availability
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.
Patent Information
| Shs Outstand | 8.72M
|
| Insider Trans | -0.83%
|
| Book/sh | 2.96 |
| Cash/sh | 2.00 |
| Debt/Eq NO DEBT | 0.00 |
| 52W Range | 1.55 - 12.72 |
